Total Payments
$8,951
2024 Payments
$1,100
Companies
63
Transactions
458
Medicare Patients
1,531
Medicare Billing
$154,859
Payment Breakdown by Category
Food & Beverage$7,867 (87.9%)
Education$1,083 (12.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,867 | 434 | 87.9% |
| Education | $1,083 | 24 | 12.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $670.98 | 46 | $0 (2024) |
| Amgen Inc. | $657.46 | 33 | $0 (2023) |
| Janssen Biotech, Inc. | $544.61 | 24 | $0 (2024) |
| Genentech USA, Inc. | $530.40 | 30 | $0 (2024) |
| Merck Sharp & Dohme LLC | $505.12 | 28 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $472.53 | 22 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $417.76 | 20 | $0 (2024) |
| PFIZER INC. | $380.56 | 32 | $0 (2024) |
| Eisai Inc. | $366.11 | 16 | $0 (2024) |
| Daiichi Sankyo Inc. | $301.66 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,100 | 45 | Novartis Pharmaceuticals Corporation ($108.08) |
| 2023 | $1,573 | 68 | Merck Sharp & Dohme LLC ($151.90) |
| 2022 | $905.67 | 41 | AstraZeneca Pharmaceuticals LP ($104.38) |
| 2021 | $690.08 | 38 | PFIZER INC. ($126.66) |
| 2020 | $592.62 | 28 | SANOFI-AVENTIS U.S. LLC ($99.95) |
| 2019 | $1,690 | 104 | Genentech USA, Inc. ($207.74) |
| 2018 | $1,405 | 72 | Amgen Inc. ($232.98) |
| 2017 | $994.35 | 62 | Amgen Inc. ($269.99) |
All Payment Transactions
458 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Oncology | ||||||
| 11/12/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.61 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $38.31 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $33.74 | General |
| 10/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.45 | General |
| Category: Hematology/Oncology | ||||||
| 09/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $23.87 | General |
| Category: Oncology | ||||||
| 09/09/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.60 | General |
| 08/26/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $26.13 | General |
| Category: Oncology | ||||||
| 08/21/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $29.52 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Oncology | ||||||
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.46 | General |
| 07/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $25.33 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Oncology | ||||||
| 07/10/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $20.88 | General |
| 07/09/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 418 | 714 | $239,766 | $59,735 |
| 2022 | 5 | 81 | 116 | $49,856 | $12,933 |
| 2021 | 8 | 606 | 793 | $275,310 | $49,174 |
| 2020 | 8 | 426 | 490 | $145,797 | $33,018 |
Total Patients
1,531
Total Services
2,113
Medicare Billing
$154,859
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 157 | 378 | $139,860 | $36,647 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 105 | 105 | $58,905 | $12,618 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 61 | 84 | $21,252 | $5,481 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $16,920 | $3,962 | 23.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 71 | 123 | $2,829 | $1,027 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 38 | $14,060 | $3,790 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $11,985 | $2,797 | 23.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 18 | $8,928 | $2,573 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 18 | 30 | $7,590 | $2,129 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $7,293 | $1,644 | 22.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 132 | 215 | $83,850 | $14,792 | 17.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 151 | 207 | $56,698 | $8,826 | 15.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 48 | 53 | $32,012 | $7,869 | 24.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 51 | 65 | $35,425 | $6,316 | 17.8% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 153 | 182 | $30,556 | $4,230 | 13.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 24 | 24 | $16,104 | $3,391 | 21.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 28 | 28 | $14,224 | $2,762 | 19.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 19 | 19 | $6,441 | $987.90 | 15.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 159 | 205 | $58,468 | $12,216 | 20.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 99 | 108 | $42,052 | $8,839 | 21.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 33 | 33 | $18,084 | $4,031 | 22.3% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 68 | 75 | $6,050 | $2,591 | 42.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 13 | $7,678 | $2,114 | 27.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 22 | 23 | $2,827 | $1,350 | 47.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $7,100 | $1,143 | 16.1% |
About Dr. Mridula Vinjamuri, M.D
Dr. Mridula Vinjamuri, M.D is a Hematology & Oncology healthcare provider based in Kennesaw, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1063613503.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mridula Vinjamuri, M.D has received a total of $8,951 in payments from pharmaceutical and medical device companies, with $1,100 received in 2024. These payments were reported across 458 transactions from 63 companies. The most common payment nature is "Food and Beverage" ($7,867).
As a Medicare-enrolled provider, Vinjamuri has provided services to 1,531 Medicare beneficiaries, totaling 2,113 services with total Medicare billing of $154,859. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Kennesaw, GA
- Active Since 05/31/2007
- Last Updated 04/13/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063613503
Products in Payments
- KEYTRUDA (Biological) $444.97
- IMBRUVICA (Drug) $374.68
- Lenvima (Drug) $366.11
- OPDIVO (Biological) $341.50
- JEVTANA (Drug) $196.53
- TAGRISSO (Drug) $178.60
- LIBTAYO (Biological) $171.27
- IBRANCE (Drug) $162.78
- INJECTAFER (Drug) $154.83
- Orserdu (Drug) $145.38
- KRAZATI (Drug) $145.20
- PROMACTA (Drug) $139.39
- MEKINIST (Drug) $135.41
- Nplate (Biological) $134.09
- CABOMETYX (Drug) $129.82
- Avastin (Biological) $127.41
- TASIGNA (Drug) $125.22
- XTANDI (Drug) $120.36
- ADCETRIS (Biological) $115.85
- JAKAFI (Drug) $113.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.